Cambridge, United Kingdom
ViaNautis, founded in 2018 and headquartered in the United Kingdom, is innovating within the Biopharma and Biotechnology industries. With the slogan "Targeted Nanomedicines", the company is advancing cell and gene therapy through its proprietary polyNaut® nanovesicles, a non-viral delivery system that targets critical cell types including those in the CNS, lung, and immune system.
The company's technology boasts strong tolerability, low immunogenicity, and dramatically simplified manufacturing, with an ambition to make advanced therapies affordable and accessible. ViaNautis’s ability to deliver a diverse range of genetic payloads allows it to tackle conditions affecting millions, with a focus on CNS, cystic fibrosis, and immunology.
Recently, ViaNautis secured a £20.00M Series A investment on 13 November 2023, with backing from notable investors like 4BIO Capital, BGF, Cystic Fibrosis Foundation, Eli Lilly, and UCB Ventures. Strategic partnerships further solidify its position and potential for transformative impact in the field.
